Market Place
Sourcing Support
Hearing-focused biotech grabs trio of programs from Otonomy`s fire sale
30 Mar 2023 //
ENDPTS
Otonomy Announces Change in Stock Exchange Listing
22 Dec 2022 //
GLOBENEWSWIRE
Otonomy shuts shop, lays off employees after string of failures
20 Dec 2022 //
FIERCEBIOTECH
Otonomy Provides Corporate Update
19 Dec 2022 //
GLOBENEWSWIRE
Otonomy’s hearing loss drug shows no benefit in trial, tanking shares
13 Oct 2022 //
PHARMAPHORUM
Otonomy’s phase 2 backup plan fails, prompting new options
13 Oct 2022 //
FIERCEBIOTECH
Otonomy Reports Results from Clinical Evaluation of OTO-413 Higher Doses
13 Oct 2022 //
GLOBENEWSWIRE
Otonomy to End Development of OTO-313 After Study Failure >OTIC
02 Aug 2022 //
MARKETWATCH
Otonomy Reports Q2 2022 Financial Results and Provides Corporate Update
25 Jul 2022 //
GLOBENEWSWIRE
Otonomy to Report Q2 2022 Financial Results and Provide Corporate Update
18 Jul 2022 //
GLOBENEWSWIRE
Otonomy to Participate in the H.C. Wainwright Global Investment Conference
18 May 2022 //
GLOBENEWSWIRE
Otonomy Announces OTO-825 Presentation at the ASGCT
12 May 2022 //
GLOBENEWSWIRE
Otonomy Reports First Quarter 2022 Financial Results
09 May 2022 //
GLOBENEWSWIRE
Otonomy to Report Q1 2022 Financial Results and Provide Corporate Update
02 May 2022 //
GLOBENEWSWIRE
Otonomy Reports Positive Top-Line Results from Phase 2a Trial of OTO-413
20 Apr 2022 //
GLOBENEWSWIRE
Otonomy Reports Q4 and Full Year 2021 Financial Results
28 Feb 2022 //
GLOBENEWSWIRE
Otonomy to Host Virtual Investor R&D Event on March 22, 2022
25 Feb 2022 //
GLOBENEWSWIRE
Otonomy Completes Enrollment in Phase 2 Clinical Trial of OTO-313 in Tinnitus
22 Feb 2022 //
GLOBENEWSWIRE
Otonomy Announces Multiple Presentations at Neuroscience 2021 Meeting
27 Oct 2021 //
GLOBENEWSWIRE
Otonomy Announces Publication of Phase 1/2 Trial Results Showing Tinnitus
12 Oct 2021 //
GLOBENEWSWIRE
Otonomy Announces Presentation of OTO-413 Clinical Results at AAO-HNS
27 Sep 2021 //
GLOBENEWSWIRE
Otonomy Appoints Jill Broadfoot to Board of Directors
19 Aug 2021 //
GLOBENEWSWIRE
Otonomy Initiates Expansion of Ph 1/2 Clinical Trial for OTO-413 in Hearing Loss
15 Jun 2021 //
GLOBENEWSWIRE
Otonomy and AGTC Present Preclinical Proof-of-Concept Results for OTO-825
14 May 2021 //
GLOBENEWSWIRE
Otonomy and AGTC to Present Preclinical Proof-of-Concept Results for OTO-825
28 Apr 2021 //
GLOBENEWSWIRE
Otonomy Initiates Phase 2 Clinical Trial of OTO-313 in Tinnitus
25 Mar 2021 //
BIOSPACE
Otonomy`s resurrected ear drug is now dead again — and investors aren`t hanging
22 Feb 2021 //
ENDPTS
Otonomy fails phase 3, adding another twist to ear disease saga
22 Feb 2021 //
FIERCEBIOTECH
Otonomy Announces Multiple Presentations at for Research Otolaryngology
18 Feb 2021 //
GLOBENEWSWIRE
Otonomy Announces Multiple Presentations at Association in Otolaryngology
17 Feb 2021 //
GLOBENEWSWIRE
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
30 Nov 2020 //
GLOBENEWSWIRE
Otonomy Provides Update on OTIVIDEX® and OTO-313 Programs
29 Nov 2020 //
GLOBENEWSWIRE
Otonomy Announces Agreement with Kyorin for Novel Compound in OTO-6XX
03 Aug 2020 //
GLOBENEWSWIRE
Otonomy Provides Update on OTIVIDEX® Program
06 Jul 2020 //
GLOBENEWSWIRE
Otonomy Reports Positive Top-Line Results from Ph1/2 Clinical Trial of OTO-313
06 Jul 2020 //
GLOBENEWSWIRE
Otonomy Provides Update on Clinical Trials and Development Programs
15 Jun 2020 //
GLOBENEWSWIRE
Otonomy Announces Presentation of OTO-313 Results at American Neurotology
05 Apr 2020 //
BIOSPACE
